According to numerous recent publications, the COVID-19 patients have lymphopenia, higher infection-related biomarkers and several elevated inflammatory cytokines (i.e. tumor necrosis factor (TNF)-α, interleukin IL-2R and IL-6). The total number of B cells, T cells and NK cells are significantly decreased. RNA viruses, SARS-CoV-2 included, hit the innate immune system in order to cause infection, through TLRs 3, 7 and 8. Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity. Preclinical and clinical trials are proposed.

中文翻译：

---

咪喹莫特 - 一种 Toll 样受体 7 激动剂 - 是治疗 COVID 19 的理想选择。

根据最近的大量出版物，COVID-19 患者出现淋巴细胞减少、感染相关生物标志物升高以及多种炎症细胞因子（即肿瘤坏死因子 (TNF)-α、白细胞介素 IL-2R 和 IL-6）升高。B细胞、T细胞和NK细胞总数明显减少。RNA 病毒（包括 SARS-CoV-2）通过 TLR 3、7 和 8 攻击先天免疫系统以引起感染。咪喹莫特是一种免疫刺激剂，可激活 TLR 7，可用于增强先天免疫和适应性免疫。提议进行临床前和临床试验。